Literature DB >> 10890316

HCV: epidemiology, modes of transmission and prevention of spread.

P Pradat1, C Trépo.   

Abstract

Approximately 3% of the world's population has been infected with the hepatitis C virus (HCV), which represents about 170 million chronic carriers at risk of developing serious complications. Following the introduction of screening of blood donors for infection the risk of transmitting HCV by blood products is presently at 1/200,000 units distributed. Intravenous (i.v.) drug users are currently the main risk group with a prevalence rate of about 80% and a yearly incidence varying between 4 and 6%. Vertical and sexual transmissions have also been implicated but data are limited and sometimes controversial. The source of infection for the 30% of cases without an identifiable risk factor remains to be clarified. Prevention of spread includes detailed information of persons at risk of being infected, screening of high-risk populations, strengthening of syringe exchanges among i.v. drug users and strict application of disinfection procedures for all invasive medical equipment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890316     DOI: 10.1053/bega.1999.0070

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Gastroenterol


  5 in total

Review 1.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS).

Authors:  Toni Frederick; Pamela Burian; Norah Terrault; Mardge Cohen; Michael Augenbraun; Mary Young; Eric Seaberg; Jessica Justman; Alexandra M Levine; Wendy J Mack; Andrea Kovacs
Journal:  AIDS Patient Care STDS       Date:  2009-11       Impact factor: 5.078

3.  Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit.

Authors:  Maria Alma Bracho; María José Gosalbes; David Blasco; Andrés Moya; Fernando González-Candelas
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation.

Authors:  Di Han; Huiqun Wang; Baerlike Wujieti; Beibei Zhang; Wei Cui; Bo-Zhen Chen
Journal:  Comput Struct Biotechnol J       Date:  2021-04-20       Impact factor: 7.271

5.  Assessment of hepatitis C risk factors in center of Iran: A case-control study.

Authors:  Faramarz Shahriari-Fard; Sayed Moayed Alavian; Ziba Farajzadegan; Ali Rabiei; Behrooz Ataei; Mehdi Ataie
Journal:  J Res Med Sci       Date:  2018-10-26       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.